Metabonomic study of metformin in type II diabetic rats
10.3969/j.issn.1001-1978.2019.09.007
- Author:
Xiao-Hui ZENG
1
Author Information
1. Guangdong Province Engineering Technology Research Institute of T.C.M.
- Publication Type:Journal Article
- Keywords:
Bile acids;
Biomarker;
Fatty acid;
Metabolic profile;
Metformin;
Type 2 diabetic melitus
- From:
Chinese Pharmacological Bulletin
2019;35(9):1212-1220
- CountryChina
- Language:Chinese
-
Abstract:
Aim To study the mechanism of metformin in the treatment of type 2 diabetic melitus (T2DM) rats. Methods Rats were randomly divided into normal group, model group and metformin group with 10 rats in each group. Four weeks after induction with HFSD, 35 mg 'kg-1 STZ was injected intramuscularly, and the experiment was completed after 8 weeks of administration. UPLC/ESI-TOF-MS was used to study the effects of metformin on metabolites in serum of T2DM rats, and qPCR was used to find its target. Results Compared with normal group, the body weight, pancreatic index and insulin level in model group decreased significantly (P < 0. 05) , liver index, GLU, TC, TG and FFA levels increased significantly (P < 0.01), OGTT was significantly impaired, while met-formin could significantly increase body weight, pancreatic index and insulin level (P <0. 05) , reduce liver index, GLU, TC, TG and FFA levels (P < 0. 05) , and improve OGTT. After metahonomics, 17 biomark-ers were obtained. After verification, metformin was found to regulate the synthesis and metabolism of cholesterol, fatty acids, bile acids and phospholipids. Conclusions Metformin can improve the lipid metabolism disorder of T2DM by regulating the synthesis and metabolism of cholesterol, fatty acids, bile acids and phospholipids.
